Inferensys

Glossary

Federated Cohort Discovery

A privacy-preserving distributed query technique that allows researchers to identify and count patient populations matching specific clinical criteria across multiple institutions without moving or exposing the underlying patient-level data.
Stylish WeWork-like workspace with hot desks and document wall, professional searching through enterprise knowledge base on a mounted ultrawide display, warm industrial pendants overhead.
PRIVACY-PRESERVING PATIENT IDENTIFICATION

What is Federated Cohort Discovery?

A distributed query technique enabling researchers to count patient populations matching clinical criteria across institutions without moving protected health information.

Federated Cohort Discovery is a privacy-preserving distributed query technique that enables researchers to identify and count patient populations matching specific clinical criteria across multiple institutions without moving or exposing the underlying patient-level data. The architecture sends a computable phenotype—a machine-executable algorithm defining inclusion and exclusion criteria—to each participating site, where it executes locally against standardized data models like OMOP Common Data Model.

Each site returns only aggregate counts and contingency tables to a central distributed query engine, which assembles the partial results into a harmonized feasibility assessment. This approach satisfies HIPAA and GDPR requirements by ensuring protected health information never leaves the local firewall, while still allowing sponsors to determine whether sufficient eligible patients exist across a network before initiating a multi-site clinical trial.

PRIVACY-PRESERVING ARCHITECTURE

Key Features of Federated Cohort Discovery

Federated Cohort Discovery decomposes a clinical query into executable sub-queries distributed across institutional nodes, returning only aggregate counts. This architecture eliminates the need for a centralized data warehouse while enabling multi-site patient population feasibility assessments.

01

Distributed Query Engine

A Distributed Query Engine receives a single analytical request and decomposes it into site-specific sub-queries. Each sub-query is dispatched to a remote node where it executes locally against the institution's native data model.

  • Translates logical cohort criteria into local dialect (e.g., OMOP, i2b2)
  • Executes aggregate-only operations: COUNT, SUM
  • Assembles partial results into a harmonized final answer
  • Never requests or retrieves patient-level rows
Zero
Patient Rows Moved
02

Computable Phenotype Execution

A Computable Phenotype is a machine-executable algorithm that defines cohort membership using structured clinical logic. Unlike free-text descriptions, it eliminates human ambiguity.

  • Composed of inclusion and exclusion criteria
  • References standardized terminologies: SNOMED CT, LOINC, RxNorm
  • Combines diagnosis codes, lab values, medication orders, and temporal constraints
  • Example: HbA1c > 9.0 within 6 months AND Type 2 Diabetes diagnosis AND no insulin prescription
03

Aggregate-Only Response Protocol

The cardinal rule of federated discovery: nodes return only aggregate statistics, never individual records. This is enforced cryptographically or architecturally.

  • Responses are limited to contingency tables and count vectors
  • Prevents reconstruction of individual patient trajectories
  • Satisfies Data Use Agreements and regulatory requirements
  • Enables honest-broker architectures where a neutral third party validates query safety
04

Heterogeneity Assessment

Before pooling results, the system performs a Heterogeneity Assessment to determine if site-specific counts are statistically compatible. Significant variability may indicate differences in coding practices or population demographics.

  • Quantified via I-squared statistic or Cochran's Q test
  • High heterogeneity triggers a review of local phenotype execution
  • Prevents misleading global counts that mask site-specific divergence
  • Outputs often visualized as a forest plot of per-site cohort sizes
05

OMOP Common Data Model Alignment

Federated discovery achieves semantic interoperability by mapping local data to the OMOP Common Data Model maintained by OHDSI. This standardization ensures a concept like 'Myocardial Infarction' maps identically across sites.

  • Standardized vocabularies eliminate lexical mismatches
  • Enables the same computable phenotype to run unmodified at every node
  • Transforms heterogeneous EHR schemas into a unified analytics surface
  • Facilitates cross-institutional Real-World Evidence generation
06

Secure Aggregation Protocol

A Secure Aggregation Protocol cryptographically ensures that the central coordinator learns only the sum of all site counts, not any individual site's contribution. This protects against honest-but-curious intermediaries.

  • Uses secure multi-party computation or additive secret sharing
  • Each site's count is masked before transmission
  • Masks cancel out during aggregation, revealing only the total
  • Critical for competitive or sensitive feasibility assessments
FEDERATED COHORT DISCOVERY

Frequently Asked Questions

Clear answers to common questions about privacy-preserving distributed query techniques for identifying patient populations across multiple institutions.

Federated cohort discovery is a privacy-preserving distributed query technique that allows researchers to identify and count patient populations matching specific clinical criteria across multiple institutions without moving or exposing the underlying patient-level data. The process works by distributing a standardized query—typically expressed in a common data model like OMOP—to each participating site's local database. Each site executes the query locally, computing only aggregate counts and summary statistics, then returns these de-identified results to a central coordinating node. The coordinator assembles the partial results into a unified view, enabling researchers to assess total cohort size and site-level feasibility before initiating a study. Critically, no individual patient records, protected health information (PHI), or identifiable data ever leave the originating institution. This architecture satisfies both HIPAA regulatory requirements and the practical need for multi-site clinical research feasibility assessment.

Prasad Kumkar

About the author

Prasad Kumkar

CEO & MD, Inference Systems

Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.

His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.